Earnings Call Summary | Know Labs(KNW.US) Q1 2024 Earnings Conference
Earnings Call Summary | Know Labs(KNW.US) Q1 2024 Earnings Conference
The following is a summary of the Know Labs, Inc. (KNW) Q1 2024 Earnings Call Transcript:
以下是Know Labs, Inc.（KNW）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Know Labs reported a Q1 net loss of $3.45 million, down 9.8% from a net loss of $3.82 million in Q1 fiscal '23.
Earnings per share improved by 50% to a loss of $0.04.
A non-cash charge of $792,000 was recorded, primarily due to stock-based compensation of $699,000.
Research and development expenditures for Q1 fiscal '24 were down 14.7% YoY at $1.48 million.
Selling, general, and administrative expenses for Q1 '24 increased by 5.6% YoY to $2.01 million, mainly due to increased salaries.
The company ended the quarter with cash and cash equivalents of $4.82 million.
Know Labs報告稱，第一季度淨虧損爲345萬美元，較23財年第一季度的382萬美元淨虧損下降9.8％。
每股收益增長了50％，至虧損0.04美元。
記錄的非現金費用爲79.2萬美元，這主要是由於股票薪酬爲69.9萬美元。
24財年第一季度的研發支出同比下降14.7％，至148萬美元。
24年第一季度的銷售、一般和管理費用同比增長5.6％，達到201萬美元，這主要是由於工資的增加。
該公司在本季度末的現金及現金等價物爲482萬美元。
Business Progress:
業務進展：
Know Labs is proactively working on optimizing its Gen 1 portable device that non-invasively monitors glucose levels.
Internal trials conducted in Q1 2024 provided insights into hyper and hypoglycemic ranges, with plans to diversify the population for future trials.
Efforts are being directed at refining the algorithm to achieve a mean absolute relative difference (MARD) of 10% or less, meeting FDA's accuracy requirements across different glycemic ranges.
The company expanded its intellectual property portfolio to 264 patents, primarily focused on their radio frequency spectroscopy technology.
Know Labs added new members to its Board of Directors and advisory board to strengthen expertise across various workstreams.
Plans are in place for participation in the 17th International Conference on Advanced Technologies, where they will present updates on their non-invasive glucose monitor and results from ongoing clinical research.
The company has reduced its core monthly burn rate, providing the company with sufficient cash to operate until at least June 30, 2024.
They plan to raise additional funds through equity issuance, preferred stock, and convertible debentures and have an $18 million S-3 shelf registration statement filed and declared effective.
Know Labs is focusing on developing the second generation of its product family and exploring revenue generation outside the U.S. without needing FDA approval.
Know Labs正在積極優化其第一代便攜式設備，該設備可以非侵入性地監測血糖水平。
2024年第一季度進行的內部試驗提供了對高血糖和低血糖範圍的見解，並計劃爲未來的試驗提供人群多樣化。
正在努力完善算法，使平均絕對相對差（MARD）達到或更低的10％，以滿足FDA在不同血糖範圍內的準確性要求。
該公司將其知識產權組合擴展到264項專利，主要側重於其射頻光譜技術。
Know Labs 爲其董事會和顧問委員會增加了新成員，以加強各個工作流程的專業知識。
參加第17屆國際先進技術會議的計劃已經制定，他們將在會上介紹其非侵入性血糖監測儀的最新情況和正在進行的臨床研究的結果。
該公司降低了每月核心消耗率，爲公司提供了足夠的現金來運營至少到2024年6月30日。
他們計劃通過股票發行、優先股和可轉換債券籌集更多資金，並提交了1800萬美元的S-3貨架註冊聲明並宣佈生效。
Know Labs專注於開發其產品系列的第二代產品，並探索在美國以外地區創收的途徑，而無需FDA批准。
More details: Know Labs IR
更多詳情： 了解實驗室 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。